Expert Analysis

New Advances in Hepatitis C

Source: CCO Independent Conference Coverage of the 2008 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

New Advances in Hepatitis C

Faculty:

Alfredo Alberti, MD
Peter Ferenci, MD
Michael P. Manns, MD

CME CREDIT INFORMATION

Release Date: 06/25/08

Expiration Date: 06/24/09

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.2 Nursing CE credits

Pharmacists: 1.2 contact hours (0.12 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Recount data comparing the efficacy of different formulations of peginterferon in hepatitis C virus infection
Summarize data regarding the efficacy of various regimens for retreatment of previous nonresponders and relapsers
Discuss findings regarding the utility of low-dose maintenance therapy in hepatitis C patients
Describe data evaluating predictors of response to hepatitis C therapy

Topics covered include:

Comparison of Combination Therapy With Peginterferon alfa-2b vs Peginterferon alfa-2a
Retreatment Among Patients With Previous Treatment Failure to Standard or Pegylated Interferon-Based Regimens
HALT-C: Low-Dose Maintenance Therapy in Patients Failing to Achieve SVR
Colchicine vs Peginterferon alfa-2b: The COPILOT Trial
Relationship Between Time to HCV RNA Suppression and Likelihood of SVR
12 Weeks of Treatment in Genotype 2/3 HCV Patients With RVR
Prognostic Biomarkers Predictive of SVR
Cirrhosis Regression With HCV Treatment

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.